Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user has been taking 1mg finasteride daily for a year with no improvement in hair loss and reports low cortisol levels, sleep issues, and anxiety changes. The conversation includes discussions on the potential effects of finasteride on cortisol and neurosteroids, with suggestions to consult a doctor and consider other factors.

Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.

Creatine might increase DHT levels, potentially affecting hair loss, but its impact is debated. Some users experience hair shedding with creatine despite using finasteride, while others notice no change.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Foligain's DHT blocker is criticized for not effectively blocking DHT, with users labeling it as ineffective and overpriced. Minoxidil is mentioned as the only legitimate product in their lineup.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The conversation discusses using 0.5mg dutasteride for hair loss and the decision to switch back to finasteride pills due to insufficient suppression. It highlights the importance of drug formulation and potential issues with absorption or degradation.

The conversation is about exploring topical anti-androgens for hair loss, specifically mentioning Bicalutamide and the unpleasant smell of Spironolactone. RU58841 is unavailable, and Breezula is suggested as an alternative.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The user discusses switching from multiple vitamins to a single multivitamin pill. They also mention using oral finasteride and topical minoxidil with finasteride for hair loss treatment.

Mixing clascoterone with minoxidil involves using 99% ethanol and propylene glycol. Users discuss the effectiveness and potential side effects of this DIY solution.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.

DHT blockers like dutasteride can reduce beard thickness while improving scalp hair. Using minoxidil on the beard may help maintain its thickness.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Dutasteride at 0.5mg blocks 50% of scalp DHT, while higher doses like 1mg and 2.5mg block more, with 2.5mg blocking up to 80%. Some users report better results with lower doses, and there's confusion about the effectiveness of different dosages on scalp versus serum DHT.

Dairy may contain DHT precursors that could affect hair loss and prostate health, with some users noting reduced hair shedding after eliminating dairy. Individual responses to dairy and DHT blockers vary, with some attributing hair health to diet changes and others seeing no impact.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

Curcumin, found in turmeric, may reduce DHT levels and hair loss, similar to finasteride, but without its side effects. However, natural DHT blockers are generally considered too weak to make a significant difference in hair loss.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

RU58841 is debated for hair loss treatment; some users report positive results, while others find it ineffective or risky. It is not widely marketed due to limited effectiveness, safety concerns, and competition from existing treatments like finasteride and minoxidil.

Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.

The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.